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Abstract
Prepulse inhibition (PPI) and reactivity of the acoustic startle response are widely used
biobehavioral markers in psychopathology research. Previous studies have demonstrated that PPI
and startle reactivity exhibit substantial within-site stability; between-site stability, however, has
not been established. In two separate consortia investigating biomarkers of early psychosis,
traveling subjects studies were performed as part of quality assurance procedures in order to assess
the fidelity of data across sites. In the North American Prodromal Longitudinal Studies (NAPLS)
Consortium, 8 normal subjects traveled to each of the 8 NAPLS sites and were tested twice at each
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site on the startle PPI paradigm. In preparation for a binational study, 10 healthy subjects were
assessed twice in both San Diego and Mexico City. Intraclass correlations between and within
sites were significant for PPI and startle response parameters, confirming the reliability of startle
measures across sites in both consortia. There were between site differences in startle magnitude
in the NAPLS study that did not appear to be related to methods or equipment. In planning multi-
site studies, it is essential to institute quality assurance procedures early and establish between site
reliability to assure comparable data across sites.
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Introduction
Prepulse inhibition (PPI) and reactivity of the acoustic startle response are widely used
translational biomarkers in psychopathological research. PPI is an index of sensorimotor
gating and is used in animal and human studies to understand brain disorders such as
schizophrenia and Tourette's Disorder that are characterized by gating impairments in the
neural substrates that underlie sensory information processing 1. In the PPI paradigm, weak
lead stimuli inhibit the startle response to intense, abrupt stimuli (acoustic, visual, tactile) 2.
PPI is typically reduced in individuals with schizophrenia 3, stable with repeated within site
testing 4-10, heritable 11,12, and associated with genes of relevance to psychosis13,14,
suggesting its utility as an endophenotype and as a vulnerability marker for psychosis
risk 15.
An increasing emphasis in schizophrenia research has been in the area of early detection and
intervention. The use of biobehavioral markers such as PPI in the study of the prodromal
phase of psychosis provides a means of not only identifying individuals at greatest risk for
psychosis but also understanding neurodevelopmental abnormalities early in the course of
illness that can contribute to better informed treatment 16. Although it is possible to use
empirically derived criteria for a prodromal psychosis syndrome 17 to identify individuals at
increased risk of psychotic illness, the 2 year psychotic conversion rate is between
15-35% 18, making it difficult to recruit a sufficient number of subjects at any one site.
Therefore, multisite studies are essential to attain sufficient statistical power to investigate
the prodromal phase of illness.
For biomarkers such as PPI to be useful in multisite studies that are needed to increase
statistical power, facilitate the identification of disease risk, increase the odds of finding
uncommon genetic variation or identification of relevant subgroups however, the measures
need to be stable with repeated assessment and reliable across sites 19. Because differences
in testing conditions and procedures across sites can introduce uncontrolled variance in
experimental measures, it is essential to understand potential site differences and control
variation across sites as much as possible. Although multisite studies have investigated
PPI 19, to our knowledge, there are no published reports of between site reliability of startle
measures using normal subjects traveling between sites. This study investigated the within-
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and between-site reliability of PPI and startle reactivity in two consortia designed to identify
vulnerability markers in early psychosis: The NAPLS (North American Prodromal
Longitudinal Studies) Consortium and a UCMEXUS (University of California Institute for
Mexico and the United States).
Materials and Methods
Participants
Participants included: 1) 8 healthy subjects recruited from each of the 8 NAPLS sites
(Emory, Harvard, University of Calgary, UCLA, UCSD, UNC, Yale, Zucker Hillside) (age
19-30, 4 males and 4 females) and 2) 10 healthy subjects (ages 28-38, 4 males and 6
females), recruited from UCSD and the National Institute of Neurology and Neurosurgery
(INNN) in Mexico City. All 9 institutions received approval from their individual ethics
committees for the study. Subjects provided written informed consent after the procedures
were fully explained. Subjects were excluded if they had the following: any concomitant
medical or neurological illness, current substance abuse or dependence (excluding nicotine),
any Axis I disorders (per Structured Interview for DSM-IV) or positive family history of
psychosis.
Acoustic startle paradigm
Equipment and procedures were identical at the 8 NAPLS sites as well as between UCSD
and INNN. Manuals with equipment setup, testing procedures and instructions to subjects
were developed in English and Spanish (for INNN). A meeting was held in Boston October
2009 to train all NAPLS sites; UCSD staff visited the Mexico site in September 2009 to
train INNN using the same procedures 20.
Subjects were screened for hearing impairment (>45 dB 1000 Hz). Smokers were allowed to
smoke up to 30 min prior to startle testing to avoid nicotine withdrawal or intoxication. A
customized Startle-stimulus generating system (Grace Design Model m902 Amplifier and
Neurobehavioral Systems Presentation software) developed by the UCSD site was used for
all sites. The sound was calibrated at all sites using a Quest 210 Sound Level Meter and a
custom-made PPI calibration session to ensure 70dB for background noise and 115dB for
extended length startle bursts at each of the sites. Neurophysiologic recordings at NAPLS
sites were performed using identical Biosemi systems and recording software (Biosemi,
Amsterdam, Netherlands). For the UCMEXUS study, data were recorded using NeuroScan
equipment and software (NuAmps Digital EEG Amplifier, Neuro Scan Labs, Sterling, VA).
Electrodes (Ag/AgCl) were placed below and at the outer canthus of the right eye with
resistances less than 10 kΩ 20. Startle stimuli were presented binaurally through identical
headphones (TDH-39P) at all sites. A 70 dB [A] broadband background noise was used with
a pulse (115 dB [A], 40 ms noise burst) presented either alone or following (30, 60 or 120
ms interstimulus interval; ISI) a prepulse (86 dB [A], 20 ms noise burst). The paradigm
began with a 5-minute acclimation period, then five pulse alone stimuli followed by 30 trials
consisting six trials each of the three prepulse conditions and 12 pulse alone stimuli
presented in a fixed, pseudorandom order. The paradigm ended with five more pulse alone
stimuli for a total of 40 trials. EMG activity for both consortia was analyzed at UCSD using
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Brain Vision Analyzer (Brain Vision LLC, Morrisville, NC) and high-pass filtered at 28Hz
at 12dB/Oct. Waveforms were smoothed using a 40Hz 24dB/Oct low-pass filter. All trials
were manually inspected for artifacts. Startle data were analyzed using wave-form averaging
for each of the four different trial types within each block, after applying baseline correction
and rectification of the data. The magnitude of the peak startle response (highest point
relative to baseline between 30 and 120 ms after onset of startle stimulus) was determined.
All subjects demonstrated a robust startle response to the first block of startle stimuli but
subjects who demonstrated a relative lack of startle stimulus elicited eye blink to the second
block of startle stimuli in any test session were excluded per established methods 20. The
following startle measures were examined: 1) reactivity, or the mean magnitude of response
to pulse alone stimuli, and 2) prepulse inhibition (PPI), the percentage of change in startle
magnitude to prepulse +pulse versus pulse-alone trials ((pulse –prepulse + pulse)/
pulse)*100). The stability of the startle measures between and within sites was assessed
using intraclass correlations (ICC; Random, Consistency Model) and repeated measures
analysis of variance (ANOVA) design. All subjects were tested twice at each site and
traveled to the other sites within 3 months for NAPLS and within 1 year (Mean 5.5 months)
for UCMEXUS. The order of testing was balanced across sites in both studies with a
specified order for NAPLS subjects starting with the home site and within the 9 subjects
who were included in the UCMEXUS study (5 at UCSD first, 4 at INNN first).
Results
As shown in Table 1, within site ICCs of startle and PPI variables were significant across all
reactivity and PPI conditions in both NAPLS and UCMEXUS (Table 1). Between-site
analyses were similarly performed comparing time 1 to time 1 and time 2 to time 2 across
sites. All but the 30 ms PPI (p=0.056) condition for UCMEXUS were significant. Finally,
within- and between-site ICCs were calculated using both sessions at each of the sites and
all were significant. In repeated measures ANOVA of PPI (NAPLS: 8 Sites X 2 sessions X 3
ISIs; UCMEXUS: 2 Sites X 2 sessions X 3 ISIs) there were no statistical site (NAPLS:
F[7,108]=0.45, ns; UCMEXUS: F[1,9]=0.51, ns) or session (NAPLS: F[1,108]=0.72, ns;
UCMEXUS: F[1,9]=0.83, ns) main or interaction effects supporting the within- and
between-site reliability. In contrast, a repeated measures ANOVA of startle reactivity
(NAPLS: 8 sites X 2 times X 3 blocks; UCMEXUS: 2 sites X 2 times X 3 blocks) revealed a
significant site effect (F[7,28]=2.46, p<0.05) for the NAPLS study due to one site having
greater startle amplitude relative to the other sites (see Figure 1), but no session or
interaction effects. When NAPLS site 4 was removed from the analysis, the significant site
effect was no longer present (F[6,30]=1.97, ns). The site main effect for UCMEXUS
(F[1,9]=0.48, ns) was non-significant as were session and interaction effects.
Discussion
This is the first report of between-site reliability of PPI and startle reactivity measured with
traveling subjects. The present findings replicate previous studies that demonstrate within-
site stability of startle measures in normal and schizophrenia spectrum subjects 4-10 and
extend these findings to demonstrate measurement comparability across laboratories in two
separate multisite studies using 2 different types of equipment for neurophysiologic
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recording. It is likely that the standardization of equipment, protocols, training, analysis and
quality assurance procedures across sites contributed to the observed consistency of startle
data.
Although startle reactivity was stable both within- and between-sites, significant site
differences were observed in the NAPLS study driven by larger startle amplitude at one of
the sites, prompting a review of equipment settings, stimulus calibration, ambient acoustic
noise, electrical noise, placement of electrodes, subject instructions, and testing environment
across sites. A decibel meter from UCSD was mailed to the site in question (site 4) to assure
the loudness of the startle stimuli was accurate and consistent across sites. No
methodological or equipment differences were identified. Individual subject data revealed
that three subjects had larger startle responses at site 4 (Figure 2), accounting for the site
differences. One subject with a large startle response was first exposed to the startle stimuli
at site 4, perhaps accounting for the larger response. Since each subject began their travels at
their home site, it is unlikely that order effects account for the observed differences. Thus,
despite institution of careful quality assurance procedures, identical subjects, methodology
and equipment, site differences still occur and need to be examined and controlled for in
biomarker studies. Future analyses of NAPLS consortium data will continue to examine site
differences in reactivity and site will be used as a between subjects factor.
A limitation of the 2 studies is the relatively small sample size in each (NAPLS included 8
subjects tested at 8 sites and UCMEXUS included 10 subjects tested at 2 sites). The sample
sizes, however, are consistent with the few traveling subjects studies performed to establish
reliability of neuroimaging measures across sites 22,23. Although future between-site
biomarker reliability studies should ideally use more subjects, sending multiple subjects to
different cities and countries for multiple testing sessions obviously presents financial and
logistical challenges.
Conclusion
In planning multi-site biomarker studies, it is essential to institute standardized quality
assurance procedures prior to data collection of targeted research samples. The use of
identical equipment, training and similar testing environments appears to be useful to
minimize sources of cross-site variance in electrophysiological studies. The observed
reliability of startle measures across laboratories provides support for the utility of these
measures as biomarkers and endophenotypes in large multisite studies. Investigation and
statistical control of potential site differences is essential in any multisite biomarker study.
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Site differences in startle reactivity were evident in the NAPLS consortium. Data represents
estimated marginal means that collapsed two test sessions at each site.
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Individual traveling subjects data from the NAPLS consortium demonstrates that 3 subjects
accounted for the observed site differences. Data represents estimated marginal means that
collapse both test sessions and 3 blocks of startle magnitude in response to pulse alone
stimuli.
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Table 1
Intraclass Correlations (ICC – Random/Consistency Model) of startle reactivity and Prepulse Inhibition (PPI)
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